Corcept Therapeutics Incorporated Common Stock Earnings Dividend

Corcept Therapeutics Incorporated Common Stock’s revenue jumped 4.89% since last year same period to $164.9Mn in the Q1 2026. On a quarterly growth basis, Corcept Therapeutics Incorporated Common Stock has generated -18.42% fall in its revenue since last 3-months.

Corcept Therapeutics Incorporated Common Stock’s net profit fell -251.86% since last year same period to $-31.2Mn in the Q1 2026. On a quarterly growth basis, Corcept Therapeutics Incorporated Common Stock has generated -228.47% fall in its net profits since last 3-months.

Corcept Therapeutics Incorporated Common Stock’s net profit margin fell -244.78% since last year same period to -18.92% in the Q1 2026. On a quarterly growth basis, Corcept Therapeutics Incorporated Common Stock has generated -257.46% fall in its net profit margins since last 3-months.

Corcept Therapeutics Incorporated Common Stock’s price-to-earnings ratio after this Q1 2026 earnings stands at 190.43.

Corcept Therapeutics Incorporated Common Stock’s earning per share (EPS) estimates for the current quarter stand at 0.04 - a 128.57% jump from last quarter’s estimates.

Corcept Therapeutics Incorporated Common Stock’s earning per share (EPS) estimates for the current year stand at 0.04.

Corcept Therapeutics Incorporated Common Stock’s earning per share (EPS) fell -276.47% since last year same period to -0.3 in the Q1 2026. This indicates that the Corcept Therapeutics Incorporated Common Stock has generated -276.47% annual rate of fall in its earning per share (EPS) in the last 4 quarters.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Corcept Therapeutics Incorporated Common Stock’s return on assets (ROA) stands at -0.01.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Corcept Therapeutics Incorporated Common Stock’s return on equity (ROE) stands at 0.07.